Relapsed or Refractory Plasma Cell Neoplasms
Conditions
Keywords
Relapsed and Refractory Plasma Cell Neoplasms., BCMA, CD70, CAR-T
Brief summary
This is a single arm study to evaluate the safety and efficacy of CAR70-BCMA dual-target CAR-T cell therapy for relapsed and refractory plasma cell neoplasms.
Interventions
GENETICCAR 70-BCMA CAR-T
Each subject will receive a single infusion of BCMA-CD70-CAR-T cells. A classic "3+3" dose escalation design will be employed.
Sponsors
The General Hospital of Western Theater Command
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. The subject or their legally authorized representative has provided written informed consent and is willing and able to comply with scheduled visits, study treatment, laboratory tests, and other study procedures 2. Diagnosis of relapsed or refractory plasma cell neoplasms, defined as follows: * Clonal plasma cells positive for BCMA and/or CD70 expression as determined by flow cytometry or immunohistochemistry * Patients with multiple myeloma, plasmacytoma, or plasma cell leukemia who have received at least three prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody, and whose best response was less than partial response (PR) or who experienced disease progression after achieving at least PR * Patients with systemic light chain amyloidosis who have received at least two prior lines of therapy, including an anti-CD38 monoclonal antibody and either a proteasome inhibitor (PI) or an immunomodulatory agent (IMiD), and whose best response was less than partial response (PR) or who experienced disease progression after achieving at least PR 3. Aged 18 to 75 years (inclusive), male or female 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 5. Life expectancy greater than 3 months from the date of informed consent 6. Hemoglobin (HGB) ≥ 60 g/L (transfusion permitted) 7. Adequate hepatic, renal, cardiac, and pulmonary function meeting the following criteria: * Creatinine ≤ 2 × upper limit of normal (ULN) * Left ventricular ejection fraction (LVEF) ≥ 50% * Oxygen saturation \> 90% * Total bilirubin ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN 8. The subject agrees to use contraceptive measures from the time of signing the informed consent form until 1 year after CAR-T cell infusion
Exclusion criteria
* Severe cardiac dysfunction with left ventricular ejection fraction (LVEF) \< 50% * History of severe pulmonary function impairment * Concurrent progressive malignancy * Concurrent severe infection that cannot be adequately controlled * Concurrent severe autoimmune disease or congenital immunodeficiency * Active hepatitis, defined as hepatitis B virus deoxyribonucleic acid (HBV-DNA) or hepatitis C virus ribonucleic acid (HCV-RNA) above the lower limit of detection * Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection * History of severe allergic reaction to biological products (including antibiotics) * Patients who have undergone allogeneic hematopoietic stem cell transplantation and still have acute graft-versus-host disease (GVHD) one month after discontinuation of immunosuppressive agents * Presence of any other serious physical or mental illness, or laboratory abnormality that may increase the risk of study participation, interfere with the interpretation of study results, or render the patient unsuitable for study enrollment in the opinion of the investigator * Female patients of childbearing potential who are pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety of CAR70-BCMA dual-target chimeric antigen receptor T-cell therapy in patients with relapsed or refractory plasma cell neoplasms expressing CD70 and/or BCMA based on the incidence of treatment-emergent adverse events (AEs). | Up to 3 years | Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0 |
| To evaluate the safety of CAR70-BCMA CAR-T cells in the treatment of relapsed or refractory plasma cell neoplasms positive for CD70/BCMA based on the determination of the maximum tolerated dose (MTD). | Up to 28 days after CAR-T treatment | Incidence of dose-limiting toxicity (DLT) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the efficacy of CAR70-BCMA CAR-T cells in the treatment of relapsed or refractory plasma cell neoplasms positive for CD70/BCMA based on the objective response rate (ORR). | Within 3 months following infusion of CAR70-BCMA CAR-T cells | Objective response rate (ORR) Description: For multiple myeloma (plasma cell neoplasms, plasma cell leukemia), the efficacy evaluation criteria refer to the Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (2024 Revision). ORR includes the proportion of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), and minimal response (MR). |
Countries
China
Contacts
CONTACTHai Yi
Outcome results
None listed